These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34329779)

  • 1. Eligibility criteria and clinical trials: An FDA perspective.
    Duggal M; Sacks L; Vasisht KP
    Contemp Clin Trials; 2021 Oct; 109():106515. PubMed ID: 34329779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exclusion of pregnant and lactating persons from breast cancer clinical trials: a review of active trials registered on ClinicalTrials.gov.
    Metcalfe A; Stephenson N; Cairncross ZF; Scime NV; Fidler-Benaoudia M
    Acta Obstet Gynecol Scand; 2024 Apr; 103(4):707-715. PubMed ID: 37377224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022.
    Xiao H; Vaidya R; Hershman DL; Unger JM
    J Clin Oncol; 2024 Jun; 42(16):1953-1960. PubMed ID: 38537158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of worldwide clinical trials by gender: An FDA perspective.
    Ayuso E; Geller RJ; Wang J; Whyte J; Jenkins M
    Contemp Clin Trials; 2019 May; 80():16-21. PubMed ID: 30890465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eligibility and enrollment of pregnant and breastfeeding women in psychiatry randomized controlled trials.
    Leung F; Miljanic S; Fernandes V; Tabbara N; De Castro C; Burry L; Jorgensen SC
    Arch Womens Ment Health; 2023 Jun; 26(3):353-359. PubMed ID: 37106141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inclusion of pregnant and breastfeeding women in research - efforts and initiatives.
    Illamola SM; Bucci-Rechtweg C; Costantine MM; Tsilou E; Sherwin CM; Zajicek A
    Br J Clin Pharmacol; 2018 Feb; 84(2):215-222. PubMed ID: 28925019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of FDA and EMA Pregnancy and Lactation Labeling.
    Kappel D; Sahin L; Yao L; Thor S; Kweder S
    Clin Pharmacol Ther; 2023 Jun; 113(6):1251-1257. PubMed ID: 36645246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Approach to Simplifying and Harmonizing Cancer Clinical Trials-Standardizing Eligibility Criteria.
    Gerber DE; Singh H; Larkins E; Ferris A; Forde PM; Selig W; Basu Roy U
    JAMA Oncol; 2022 Sep; 8(9):1333-1339. PubMed ID: 35925576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the inclusion of pregnant and breastfeeding people in infectious diseases randomized controlled trials: a targeted literature review.
    Jorgensen SCJ; Miljanic S; Tabbara N; Somanader D; Tse CLY; De Castro C; Malhamé I; LapinskY SE; Burry L
    Clin Microbiol Infect; 2022 Jun; 28(6):801-811. PubMed ID: 34768020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of pregnancy and lactation postmarketing studies required by the FDA.
    Krastein J; Sahin L; Yao L
    Pharmacoepidemiol Drug Saf; 2023 Mar; 32(3):287-297. PubMed ID: 36401739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002.
    Yang Y; Carlin AS; Faustino PJ; Motta MI; Hamad ML; He R; Watanuki Y; Pinnow EE; Khan MA
    J Womens Health (Larchmt); 2009 Mar; 18(3):303-10. PubMed ID: 19243271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Underserved groups remain underserved as eligibility criteria routinely exclude them from breast cancer trials.
    Moloney C; Shiely F
    J Clin Epidemiol; 2022 Jul; 147():132-141. PubMed ID: 35341945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.
    Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS
    Trials; 2016 Apr; 17():199. PubMed ID: 27079511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotics Approved for Marketing in Populations Specifically Excluded From Premarketing Trials, 1999-2018.
    Kuzucan A; Powers JH; Doshi P
    Mayo Clin Proc; 2020 Dec; 95(12):2699-2703. PubMed ID: 33276841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exclusion of Women of Childbearing Potential in Clinical Trials of Type 2 Diabetes Medications: A Review of Protocol-Based Barriers to Enrollment.
    Phelan AL; Kunselman AR; Chuang CH; Raja-Khan NT; Legro RS
    Diabetes Care; 2016 Jun; 39(6):1004-9. PubMed ID: 27208329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The causes and effects of socio-demographic exclusions from clinical trials.
    Bartlett C; Doyal L; Ebrahim S; Davey P; Bachmann M; Egger M; Dieppe P
    Health Technol Assess; 2005 Oct; 9(38):iii-iv, ix-x, 1-152. PubMed ID: 16181564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demographic Diversity of Clinical Trials for Therapeutic Drug Products: A Systematic Review of Recently Published Articles, 2017-2022.
    Chege W; Poddar A; Samson ME; Almeida C; Miller R; Raafat D; Fakhouri T; Fienkeng M; Omokaro SO; Crentsil V
    J Clin Pharmacol; 2024 May; 64(5):514-528. PubMed ID: 38098162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
    Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
    Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.